Takara Bio Inc. (FRA:TF2)

Market Cap	749.45M +16.8%
Revenue (ttm)	239.83M +2.5%
Net Income	-39.11M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (1.72%)
Ex-Dividend Date	Mar 28, 2025

Volume	n/a
Average Volume	n/a
Open	6.05
Previous Close	6.00
Day's Range	6.05 - 6.05
52-Week Range	3.84 - 6.10
Beta	n/a
RSI	68.62
Earnings Date	May 8, 2026

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and test...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 1,779
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TF2

Financial Performance

In fiscal year 2025, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.

Financial numbers in JPY